Suppr超能文献

线粒体碎片化触发骨髓增生异常综合征中无效造血。

Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes.

机构信息

Laboratory of Oncology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.

Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.

出版信息

Cancer Discov. 2022 Jan;12(1):250-269. doi: 10.1158/2159-8290.CD-21-0032. Epub 2021 Aug 30.

Abstract

Ineffective hematopoiesis is a fundamental process leading to the pathogenesis of myelodysplastic syndromes (MDS). However, the pathobiological mediators of ineffective hematopoiesis in MDS remain unclear. Here, we demonstrated that overwhelming mitochondrial fragmentation in mutant hematopoietic stem cells and progenitors (HSC/P) triggers ineffective hematopoiesis in MDS. Mouse modeling of exon deletion with mutants, previously unreported comutations in patients with MDS, recapitulated not only clinically relevant MDS phenotypes but also a distinct MDS-related gene signature. Mechanistically, dynamin-related protein 1 (DRP1)-dependent excessive mitochondrial fragmentation in HSC/Ps led to excessive reactive oxygen species production, induced inflammatory signaling activation, and promoted subsequent dysplasia formation and impairment of granulopoiesis. Mitochondrial fragmentation was generally observed in patients with MDS. Pharmacologic inhibition of DRP1 attenuated mitochondrial fragmentation and rescued ineffective hematopoiesis phenotypes in mice with MDS. These findings provide mechanistic insights into ineffective hematopoiesis and indicate that dysregulated mitochondrial dynamics could be a therapeutic target for bone marrow failure in MDS. SIGNIFICANCE: We demonstrated that excessive mitochondrial fragmentation is a fundamental pathobiological phenomenon that could trigger dysplasia formation and ineffective hematopoiesis in MDS. Our findings provide mechanistic insights into ineffective hematopoiesis and suggest dysregulated mitochondrial dynamics as a therapeutic target for treating MDS..

摘要

无效造血是导致骨髓增生异常综合征(MDS)发病的根本过程。然而,MDS 无效造血的病理生物学介质仍不清楚。在这里,我们证明突变造血干细胞和祖细胞(HSC/P)中过度的线粒体碎片化触发 MDS 中的无效造血。以前未在 MDS 患者中报道的外显子缺失突变的小鼠模型不仅重现了临床相关的 MDS 表型,而且还重现了独特的 MDS 相关基因特征。从机制上讲,HSC/P 中依赖于 dynamin-related protein 1 (DRP1) 的过度线粒体碎片化导致过多的活性氧产生,诱导炎症信号激活,并促进随后的发育异常形成和粒细胞生成受损。在 MDS 患者中通常观察到线粒体碎片化。DRP1 的药理抑制减轻了 MDS 小鼠的线粒体碎片化并挽救了无效造血表型。这些发现为无效造血提供了机制见解,并表明失调的线粒体动力学可能是 MDS 骨髓衰竭的治疗靶点。意义:我们证明了过度的线粒体碎片化是一种根本的病理生物学现象,它可以触发 MDS 中的发育异常形成和无效造血。我们的发现为无效造血提供了机制见解,并提示失调的线粒体动力学可能是治疗 MDS 的一个治疗靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验